This phase II trial tests the safety, best dose, and effectiveness of ropeginterferon alfa-2b for the treatment of patients with myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes and chronic myelomonocytic leukemia. Ropeginterferon alfa-2b is a form of interferon. Interferons are a type of signaling protein normally produced by the body as part of the immune response. Interferons interfere with the division of cancer cells and can slow cancer cell growth. Ropeginterferon alfa-2b is a long-acting form of a type of interferon called interferon alfa-2b. In the body, ropeginterferon alfa-2b causes the production of proteins that modulate the immune system and have anticancer effects.

Start Date29 Sep 2026

Sponsor / Collaborator

Jonsson Comprehensive Cancer Center

[+1]

NCT07249840

/ Not yet recruitingPhase 1IIT

Pilot Study of Ropeginterferon for Patients With JAK2 V617F Clonal Hematopoiesis and High-Risk Features

The goal of this clinical trial is to learn if the drug ropeginterferon alfa-2b can be used safely to treat patients with a JAK2 mutation and high risk features, but do not yet have a myeloproliferative neoplasm. The main questions it aims to answer are:
* Can we enroll 12 patients with JAK2 mutations and high risk features without a myeloproliferative neoplasm on a clinical trial evaluating the drug ropeginterferon?
* Is ropeginterferon safe to use in these patients?
Participants will:
* Receive ropeginterferon as an injection under the skin once every 4 weeks
* Visit the clinic every 1-3 months for checkups and tests

Start Date01 Jun 2026

Sponsor / Collaborator

The Brigham & Women's Hospital, Inc.

ChiCTR2600123248

/ Not yet recruitingNot ApplicableIIT

A Multicenter Study to Assess the Efficacy and Safety of ropeginterferon alfa-2b in young adults with Essential Thrombocythemia (ET)

Start Date05 May 2026

Sponsor / Collaborator-

100 Clinical Results associated with Ropeginterferon alfa-2b-NJFT

100 Translational Medicine associated with Ropeginterferon alfa-2b-NJFT

100 Patents (Medical) associated with Ropeginterferon alfa-2b-NJFT

253

Literatures (Medical) associated with Ropeginterferon alfa-2b-NJFT

10 Mar 2026·Blood Advances

Toward new therapy end points in polycythemia vera: targeting clonal and inflammatory pathways

Review

Author: Barbui, Tiziano ; Scandura, Joseph Michael

Abstract:

Although phlebotomy and hydroxyurea (HU) are standard first-line therapies for polycythemia vera (PV), they do not adequately address clonal expansion and chronic inflammation, which are key drivers of thrombosis, myelofibrosis, and mortality. Biomarkers such as JAK2 V617F variant allele frequency (VAF) and the neutrophil-to-lymphocyte ratio (NLR) are emerging as valuable tools for guiding therapy. Ropeginterferon alfa-2b has been shown to reduce both JAK2 VAF and NLR, improving event-free survival, as demonstrated in the Low-PV and PROUD-PV/CONTINUATION-PV trials. In contrast, propensity score matching of the European Collaborative Low-Dose Aspirin trial showed that HU has a limited effect on these biomarkers, suggesting weaker disease-modifying potential. Although no data on NLR dynamics with ruxolitinib have been published, the anti-inflammatory effects of ruxolitinib and its suppression of JAK2 VAF suggest it may exert similar biological activity. These findings support a shift toward biology-guided treatment in PV, recognizing that inflammation and JAK2 VAF could serve as surrogate end points in future clinical trials.

04 Mar 2026·Expert Review of Anticancer Therapy

Ropeginterferon alfa-2b in polycythemia vera: redefining disease control through molecular targeting

Review

Author: De Fazio, Laura ; Molica, Matteo ; Rossi, Marco

INTRODUCTION:

This review critically appraises recent clinical and translational advances on ropeginterferon alfa-2b, a long-acting, mono-pegylated interferon that has become a key therapeutic option for polycythemia vera (PV). Beyond its cytoreductive efficacy, ropeginterferon exerts immunomodulatory and antiproliferative effects that may modify disease biology. The review outlines its therapeutic rationale, pharmacologic profile, and emerging role as a disease-modifying agent compared with conventional cytoreductive therapies.

AREAS COVERED:

This article summarizes the pharmacokinetic properties, clinical efficacy, molecular activity, and safety of ropeginterferon alfa-2b across pivotal trials and real-world studies. Particular attention is given to hematologic responses, reduction of JAK2 V617F allele burden, and long-term tolerability. Data were identified through a systematic search of PubMed, Embase, and ClinicalTrials.gov for English-language studies published up to 2025.

EXPERT OPINION:

Ropeginterferon alfa-2b has redefined PV management by combining durable hematologic control with progressive molecular remission. Its favorable efficacy-toxicity balance and convenient dosing support long-term use, particularly in younger or treatment-naïve patients. Future research should refine patient selection, explore predictive biomarkers, and define its role among disease-modifying agents capable of transforming PV into a chronic, potentially controllable disorder.

01 Feb 2026·LEUKEMIA

Randomized phase 3 trial of Ropeginterferon alfa-2b versus surveillance after tyrosine kinase inhibitor discontinuation in chronic myeloid leukemia (ENDURE/CML-IX)

Article

Author: Wittenberg, Michael ; Nist, Andrea ; Michel, Christian ; Franke, Georg-Nikolaus ; Nicolini, Franck E ; Ernst, Thomas ; Lang, Fabian ; Illmer, Thomas ; Aminossadati, Behnaz ; Raifer, Hartmann ; Pauck, Kim ; Metzelder, Stephan K ; Klemm, Paul ; Saussele, Susanne ; Burchert, Andreas ; Tuere, Evin ; Höffkes, Heinz-Gert ; Krause, Stefan W ; Lechner, Marcus ; Stiewe, Thorsten ; Neubauer, Andreas ; Abu-Samra, Maisun ; Stoltefuß, Andrea ; Schafhausen, Philippe ; Kroning, Lea ; Radsak, Markus P ; Herhaus, Peter ; Lutz, Christoph ; le Coutre, Philipp ; Wang, Ying ; Göthert, Joachim R ; Oellerich, Thomas ; Gattermann, Norbert ; Winterstein, Kerstin ; Hehlmann, Rüdiger ; Weiland, Paul ; Teichmann, Lino L ; Goebeler, Maria E ; Kiessler, Lea ; Klausmann, Martine ; Garn, Holger ; Pfirrmann, Markus ; Stegelmann, Frank ; Bormann, Matthias ; Otto, Clara ; Guerci-Bresler, Agnès ; Huber, Magdalena ; Etienne, Gabriel ; Möhle, Robert ; Hochhaus, Andreas ; Crysandt, Martina ; Schade-Brittinger, Carmen ; Weber, Theresa

Abstract:

Treatment-free remission (TFR) after discontinuation of ABL tyrosine kinase inhibitors (TKIs) is an important therapeutic goal in chronic myeloid leukemia (CML). Interferon-α (IFN) has been suggested to promote durable TFR. The phase 3 ENDURE trial (NCT03117816; EUDRA-CT 2016-001030-94) prospectively tested this hypothesis in patients with stable deep molecular remission after TKI therapy. A total of 203 patients were randomised 1:1 to receive ropeginterferon alfa-2b (ropeg-IFN; 100 µg subcutaneously every two weeks for 15 months, n = 95) or observation alone (n = 108) after TKI discontinuation. The primary endpoint was molecular relapse-free survival (MRFS), defined as time to loss of major molecular response (MMR) or death. At a median follow-up of 36 months, 25-month MRFS was 56% (95% confidence interval (CI), 45–66) with ropeg-IFN and 59% (95% CI, 49–68) with observation (hazard ratio (HR), 1.02; 95% CI, 0.68–1.55; P = 0.91). Among 83 patients with molecular data after TKI restart, 79 (95%) regained at least MMR, 78 within 12 months (median 3 months, interquartile range: 2-4 months). Ropeg-IFN was well tolerated (median administered dose of 92 µg, range 3–104), and no new safety signals were observed. Ropeg-IFN maintenance did not improve the probability of sustained TFR after TKI discontinuation.

News (Medical) associated with Ropeginterferon alfa-2b-NJFT

24 Apr 2026

·www.businesswire.com

Frankfurt Higher Regional Court upholds BESREMi arbitral award in favor of AOP Health

VIENNA--(BUSINESS WIRE)--Today, the Higher Regional Court of Frankfurt upheld the February 20251 partial final ICC arbitral award in favor of AOP Orphan Pharmaceuticals GmbH (“AOP Health”) in its dispute with PharmaEssentia Corp. (“PharmaEssentia”). The ruling confirms the award which found the Taiwanese company to be liable for certain damages. The ruling confirms the award which found PharmaEssentia Corp. to be liable for certain damages. Dr. Rudolf Widmann, one of the two founders of AOP Health, explains: “We very much welcome the Frankfurt Higher Regional Court’s decision that confirms our position. In the interest of our patients, we are dedicated to maintaining stable and sustainable access to BESREMi® and to responsibly navigating future challenges.” The Product in Dispute The conflict centers around BESREMi® (ropeginterferon alfa-2b), a product launched in 2019 and developed by AOP Health into an innovative treatment for rare blood cancers, particularly polycythemia vera, through a comprehensive clinical trial program. This makes BESREMi® the best investigated interferon in clinical trials in this indication as documented in the major relevant guidelines2. AOP Health had acquired the rights for both BESREMi®’s development and commercialization in the European, Commonwealth of Independent States (CIS), and Middle Eastern markets from PharmaEssentia in 2009. In its seventh year after its approval by European Medicines Agency (“EMA”), AOP Health has successfully made BESREMi® available to an estimated 12,600 patients in AOP Health’s licensed territory. First Arbitration and Set-aside Proceedings Since 2017, PharmaEssentia repeatedly attempted to terminate its agreement with AOP Health regarding BESREMi®. In October 2020, an ICC Arbitral Tribunal rejected these attempts and awarded AOP Health approx. EUR 143 million in damages and dismissed PharmaEssentia’s counterclaims in its entirety. Subsequent set-aside proceedings confirmed the arbitral award in its essentials, but found procedural flaws with respect to damage quantification, impacting the damages awarded. Second Arbitration In November 2020, PharmaEssentia initiated a legal action against AOP Health, alleging damage claims. AOP Health in turn claimed damages for delays in BESREMi®’s European approval caused by PharmaEssentia, and the misuse of AOP Health’s clinical trial data for PharmaEssentia’s US marketing authorization. The result was a partial final ICC arbitral award in favor of AOP Health, received on 17 February 2025, which found PEC guilty of intentional breaches and liable for several claims. The tribunal’s decision on the quantum of those claims is yet to be made. Ruling of Higher Regional Court of Frankfurt Confirms AOP Health’s Position In May 2025, PharmaEssentia filed an application with the Frankfurt Higher Regional Court to set aside the partial final ICC arbitral award dated 10 February 2025, arguing among other things that the award violated public order and PharmaEssentia’s right to be heard. On 24 April 2026, the Frankfurt Higher Regional Court dismissed this application in its entirety and declared the award enforceable. An appeal to the German Federal Court of Justice is possible. AOP Health believes this decision confirms its position and reinforces its commitment to patients. The company will continue to supply patients in need of ropeginterferon alfa-2b (BESREMi®), maintaining the high standards of quality patients depend on. About BESREMi® BESREMi® is the first interferon that was approved for polycythemia vera, a myeloproliferative neoplasm (MPN), indicated in the European Union as monotherapy in adults for treatment of polycythemia vera without symptomatic enlarged spleen. Its overall safety and efficacy were demonstrated in multiple clinical studies. BESREMi® (ropeginterferon alfa-2b) is a long-acting, mono-pegylated proline interferon (ATC L03AB15). It is administered once every 2 weeks initially, or up to every 4 weeks after stabilization of blood values. BESREMi® is designed to be self-administered subcutaneously with a pre-filled pen. For the EMA Summary of Product Characteristics please visit: BESREMi® About AOP Health AOP Health is a global healthcare group with roots in Austria, where the headquarters of AOP Orphan Pharmaceuticals GmbH ("AOP Health") is located. Since 1996, the AOP Health Group has been dedicated to developing innovative solutions to address unmet medical needs, particularly in the fields of rare diseases and intensive care medicine. At the end of 2024, AOP Health received its first U.S. FDA approval for RapiblykTM, a medication aimed at patients in intensive care units, thereby further strengthening its commitment to making therapies available for patients worldwide. The AOP Health Group has established itself internationally as a pioneer in integrated therapy solutions and operates worldwide through subsidiaries, representations, and a strong network of partners. With the claim "Needs. Science. Trust." the AOP Health Group emphasizes its commitment to research and development, as well as the importance of building relationships with physicians and patient advocacy groups to ensure that the needs of these stakeholders are reflected in all aspects of the AOP Health Group’s actions. 1 https://www.aop-health.com/global_en/press/press-releases/icc-arbitral-tribunal-ruling-aop-health/ 2 ELN Guideline (2022), NCCN Guideline (2024), Onkopedia Leitlinie (2023)

Drug ApprovalPatent Infringement

24 Apr 2026

·www.aop-health.com

Frankfurt Court Upholds Arbitral Award in favor of AOP Health

Vienna, 24.04.2026. Today, the Higher Regional Court of Frankfurt upheld the February 20251 partial final ICC arbitral award in favor of AOP Orphan Pharmaceuticals GmbH (“AOP Health”) in its dispute with PharmaEssentia Corp. (“PharmaEssentia”). The ruling confirms the award which found the Taiwanese company to be liable for certain damages. Dr. Rudolf Widmann, one of the two founders of AOP Health, explains: The Product Dispute The conflict centers around BESREMi® (ropeginterferon alfa-2b), a product launched in 2019 and developed by AOP Health into an innovative treatment for rare blood cancers, particularly polycythemia vera, through a comprehensive clinical trial program. This makes BESREMi® the best investigated interferon in clinical trials in this indication as documented in the major relevant guidelines2. AOP Health had acquired the rights for both BESREMi®’s development and commercialization in the European, Commonwealth of Independent States (CIS), and Middle Eastern markets from PharmaEssentia in 2009. In its seventh year after its approval by European Medicines Agency (“EMA”), AOP Health has successfully made BESREMi® available to an estimated 12,600 patients in AOP Health’s licensed territory. First Arbitration and Set-Aside Proceedings Since 2017, PharmaEssentia repeatedly attempted to terminate its agreement with AOP Health regarding BESREMi®. In October 2020, an ICC Arbitral Tribunal rejected these attempts and awarded AOP Health approx. EUR 143 million in damages and dismissed PharmaEssentia’s counterclaims in its entirety. Subsequent set-aside proceedings confirmed the arbitral award in its essentials, but found procedural flaws with respect to damage quantification, impacting the damages awarded. Second Arbitration In November 2020, PharmaEssentia initiated a legal action against AOP Health, alleging damage claims. AOP Health in turn claimed damages for delays in BESREMi®’s European approval caused by PharmaEssentia, and the misuse of AOP Health’s clinical trial data for PharmaEssentia’s US marketing authorization. The result was a partial final ICC arbitral award in favor of AOP Health, received on 17 February 2025, which found PEC guilty of intentional breaches and liable for several claims. The tribunal’s decision on the quantum of those claims is yet to be made. Ruling of Higher Regional Court of Frankfurt Confirms AOP Health’s Position In May 2025, PharmaEssentia filed an application with the Frankfurt Higher Regional Court to set aside the partial final ICC arbitral award dated 10 February 2025, arguing among other things that the award violated public order and PharmaEssentia’s right to be heard. On 24 April 2026, the Frankfurt Higher Regional Court dismissed this application in its entirety and declared the award enforceable. An appeal to the German Federal Court of Justice is possible. AOP Health believes this decision confirms its position and reinforces its commitment to patients. The company will continue to supply patients in need of ropeginterferon alfa-2b (BESREMi®), maintaining the high standards of quality patients depend on. BESREMi® is the first interferon that was approved for polycythemia vera, a myeloproliferative neoplasm (MPN), indicated in the European Union as monotherapy in adults for treatment of polycythemia vera without symptomatic enlarged spleen. Its overall safety and efficacy were demonstrated in multiple clinical studies. BESREMi® (ropeginterferon alfa-2b) is a long-acting, mono-pegylated proline interferon (ATC L03AB15). It is administered once every 2 weeks initially, or up to every 4 weeks after stabilization of blood values. BESREMi® is designed to be self-administered subcutaneously with a pre-filled pen. For the EMA Summary of Product Characteristics please visit: BESREMi® AOP Health is a global healthcare group with roots in Austria, where the headquarters of AOP Orphan Pharmaceuticals GmbH ("AOP Health") is located. Since 1996, the AOP Health Group has been dedicated to developing innovative solutions to address unmet medical needs, particularly in the fields of rare diseases and intensive care medicine. At the end of 2024, AOP Health received its first U.S. FDA approval for RapiblykTM, a medication aimed at patients in intensive care units, thereby further strengthening its commitment to making therapies available for patients worldwide. The AOP Health Group has established itself internationally as a pioneer in integrated therapy solutions and operates worldwide through subsidiaries, representations, and a strong network of partners. With the claim “Needs. Science. Trust.” the AOP Health Group emphasizes its commitment to research and development, as well as the importance of building relationships with physicians and patient advocacy groups to ensure that the needs of these stakeholders are reflected in all aspects of the AOP Health Group’s actions. Press Contact. Mag. Nina Roth, MAS Head of Corporate Communications nina.roth[at]aop-health.com References: 1 www.aop-health.com/global_en/press/press-releases/icc-arbitral-tribunal-ruling-aop-health/2 ELN Guideline (2022), NCCN Guideline (2024), Onkopedia Leitlinie (2023) Photocredit Stock-Photo: AdobeStock_1803350112Photocredit Portrait: AOP Health/Daniel Ospelt

Drug ApprovalPatent Infringement

06 Apr 2026

·www.pharmamanufacturing.com

PharmaEssentia signs agreement for new biologics facility in Puerto Rico

PharmaEssentia, a biopharmaceutical company headquartered in Taipei, Taiwan, with a U.S. subsidiary in Burlington, Massachusetts, has signed an investment agreement for a new manufacturing facility in Toa Baja, Puerto Rico, marking a key step in establishing a dual-site manufacturing network between the two countries. According to the announcement, the facility is designed to the same standards as PharmaEssentia’s existing manufacturing site in Taichung, Taiwan, with personnel from the Puerto Rico facility expected to complete training at the Taichung site to support knowledge transfer and operational readiness. The company is planning for the facility to begin operations in 2027, pending regulatory approvals. The site is intended to support U.S. market supply, including for BESREMi (ropeginterferon alfa-2b-njft), the company’s approved treatment for polycythemia vera in adults. Ko-Chung Lin, CEO of PharmaEssentia, said in a statement that expanding manufacturing capacity outside Taiwan is a core strategic priority, with Puerto Rico serving as a key hub to support the U.S. market and the company’s commitment to patients worldwide. The agreement follows PharmaEssentia’s February 2026 announcement of plans to invest approximately $46 million to establish a wholly owned manufacturing subsidiary in Puerto Rico, which the company said is intended to enhance supply security, increase operational flexibility, and provide scalable capacity to support future growth.

Drug Approval

100 Deals associated with Ropeginterferon alfa-2b-NJFT

External Link

KEGG	Wiki	ATC	Drug Bank
D11027	Ropeginterferon alfa-2b-NJFT	L03AB15	DB15119

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Polycythemia Vera	European Union	AOP Orphan Pharmaceuticals GmbH	15 Feb 2019
Polycythemia Vera	Iceland	AOP Orphan Pharmaceuticals GmbH	15 Feb 2019
Polycythemia Vera	Liechtenstein	AOP Orphan Pharmaceuticals GmbH	15 Feb 2019
Polycythemia Vera	Norway	AOP Orphan Pharmaceuticals GmbH	15 Feb 2019

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Primary Myelofibrosis	Phase 3	Japan	PharmaEssentia Corp.	18 Jul 2025
Thrombocythemia, Essential	Phase 3	United States	PharmaEssentia Corp.	25 Aug 2020
Thrombocythemia, Essential	Phase 3	China	PharmaEssentia Corp.	25 Aug 2020
Thrombocythemia, Essential	Phase 3	Japan	PharmaEssentia Corp.	25 Aug 2020
Thrombocythemia, Essential	Phase 3	Canada	PharmaEssentia Corp.	25 Aug 2020
Thrombocythemia, Essential	Phase 3	Hong Kong	PharmaEssentia Corp.	25 Aug 2020
Thrombocythemia, Essential	Phase 3	Singapore	PharmaEssentia Corp.	25 Aug 2020
Thrombocythemia, Essential	Phase 3	South Korea	PharmaEssentia Corp.	25 Aug 2020
Thrombocythemia, Essential	Phase 3	Taiwan Province	PharmaEssentia Corp.	25 Aug 2020
Chronic phase chronic myeloid leukemia	Phase 3	France	AOP Orphan Pharmaceuticals GmbH	04 May 2017

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT06002490 (A23-301, Company_Website) Manual	Phase 3	Polycythemia Vera	-	BESREMi	bivhsqwoej(ejppbwftgg) = lgesiyfnfo khbtxocqey (sxtkzmopti )	Positive	02 Mar 2026
NCT05482971 (EXCEED-ET, Company_Website) Manual	Phase 2	Thrombocythemia, Essential	91	Ropeginterferon alfa-2b-njft (Treatment-naïve patients)	xyubuintrj(qblzsshiav) = dmplhuboyi yewostntyg (jxrowrpqwy ) View more	Positive	12 Jan 2026
NCT05482971 (EXCEED-ET, Company_Website) Manual	Phase 2	Thrombocythemia, Essential	91	Ropeginterferon alfa-2b-njft (Hydroxyurea-experienced patients)	xyubuintrj(qblzsshiav) = pipcwocryi yewostntyg (jxrowrpqwy ) View more	Positive	12 Jan 2026
ASH2025	Phase 2	Polycythemia Vera	95	Ropeginterferon alfa-2b	ssuxvsoycf(pykovlwyxv) = afqgcciirm hjabpzjshr (rsubkmhddu ) View more	Positive	06 Dec 2025
ASH2025	Phase 4	Polycythemia Vera	229	Ropeginterferon alfa-2b	mlcuzefigp(fuidfvvint) = fqrxaggrlu gjnsxtvkrq (niytiylaxv, 33.45 - 59.77) View more	Positive	06 Dec 2025
ISRCTN88102629 (FEDORA, ASH2025)	Phase 2	Myelofibrosis JAK2V617F positive	34	Fedratinib 400mg + Ropeginterferon Alfa-2b	negzvekyuq(fsnauyghze) = hcnggggcsz oiohaqlzqp (ssdfykbify ) View more	Positive	06 Dec 2025
NCT06514807 (ROP-ET, ASH2025)	Phase 3	Thrombocythemia, Essential	132	Ropeginterferon alfa-2b	dujhzxmyna(buyneuoulc) = cjveocdzsq jwtdwkbelk (lskmmbtxph )	Positive	06 Dec 2025
NCT04285086 (SURPASS ET, Pubmed \| Lancet Haematol)	Phase 3	Thrombocythemia, Essential	174	Ropeginterferon alfa-2b	nuehtpujts(dvivlcesyw) = vfaolhrvls edrxxfwvhg (jdtwblczig ) View more	Positive	01 Nov 2025
NCT04285086 (SURPASS ET, Pubmed \| Lancet Haematol)	Phase 3	Thrombocythemia, Essential	174	Anagrelide	nuehtpujts(dvivlcesyw) = cgoeopzqrn edrxxfwvhg (jdtwblczig ) View more	Positive	01 Nov 2025
NCT02370329 (CTgov)	Phase 2	Myelofibrosis \| Primary Myelofibrosis	11	Quality-of-Life Assessment+Ropeginterferon Alfa-2B	dxxjbgncqo = fvxxrktbsv lqbhgzazcp (jjsxverftv, ajpsmggoxb - xorsdudjfk) View more	-	27 Oct 2025
NCT04182100 (CTgov)	Phase 2	Polycythemia Vera	29	Phlebotomy+P1101+low-dose aspirin	nfzsdhniwk = caclpklirk laqgwxvcmn (mqwnkkpmds, yozypnulwp - psrfrralph) View more	-	15 Sep 2025
NCT04285086 (SURPASS-ET, ASCO2025)	Phase 3	Thrombocythemia, Essential Second line	174	Ropeginterferon alfa-2b	bpjmurtexj(ytinbzrraa) = giqqtgfogf iitgawqzvb (vwxucdrhrd ) View more	Positive	30 May 2025
NCT04285086 (SURPASS-ET, ASCO2025)	Phase 3	Thrombocythemia, Essential Second line	174	Anagrelide	bpjmurtexj(ytinbzrraa) = xrulkrdypy iitgawqzvb (vwxucdrhrd ) View more	Positive	30 May 2025

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis